Assuntos
Anestesiologistas , Testes Obrigatórios , Erros Médicos/prevenção & controle , Inabilitação do Médico , Detecção do Abuso de Substâncias , Transtornos Relacionados ao Uso de Substâncias/prevenção & controle , Anestesiologistas/economia , Análise Custo-Benefício , Humanos , Testes Obrigatórios/economia , Erros Médicos/economia , Segurança do Paciente , Inabilitação do Médico/economia , Desenvolvimento de Programas , Avaliação de Programas e Projetos de Saúde , Uso Recreativo de Drogas , Reprodutibilidade dos Testes , Detecção do Abuso de Substâncias/economia , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/economiaRESUMO
BACKGROUND: The opioid crisis has had a substantial financial impact on the health care system in the United States. This study evaluates how health plans have been affected financially and shows how a laboratory benefit management (LBM) program can be used to address related drug testing in an outpatient setting. METHODS: Monthly claims data from private health plans were collected from June 1, 2016 to February 29, 2020. The total number of claims (units) for definitive and presumptive drug testing were calculated and the number of paid claims recorded. Claims distribution by laboratory type and medical code billed, the paid rate and compound annual growth rate, and the test distribution and paid rate of rendering providers who had submitted a minimum of 1000 claims were determined. RESULTS: In total, 2,004,230 drug testing claims were submitted. After the LBM program was implemented, the percentage of paid claims for definitive drug testing (Healthcare Common Procedure Coding System code G0483) decreased and the paid rate for the low-cost tests (HCPCS code G0480) in physician office and independent laboratory settings increased. The compound annual growth rate for G0483 claims submitted indicated a 70.5% and 31.9% decrease in payments to physician offices and independent laboratories, respectively, for the period ending February 2020. CONCLUSIONS: An LBM program can positively address policy enforcement while reducing unnecessarily complex tests and limiting potential fraud, waste, and abuse by directing testing toward laboratories amenable to cost-efficient contractual savings. Moreover, for definitive drug testing, the enforcement of the use of Healthcare Common Procedure Coding System codes and a move toward more cost-efficient tests (G0480), when clinically applicable, supported by clinical practice guidelines, or evidence-based medicine, is an approach to providing medical benefits while maintaining health costs.
Assuntos
Seguro , Epidemia de Opioides , Detecção do Abuso de Substâncias/economia , Analgésicos Opioides , Custos de Cuidados de Saúde , Humanos , Estados Unidos/epidemiologiaRESUMO
Selective androgen receptor modulators (SARMs) are a group of anabolic enhancer drugs posing threats to the integrity of animal sports and the safety of animal-derived foods. The current research describes for the first time the development of a semi-quantitative assay for the monitoring of SARM family compounds in blood and establishes the relative stability of these analytes under various storage conditions prior to analysis. The presented screening method validation was performed in line with current EU legislation for the inspection of livestock and produce of animal origin, with detection capability (CCß) values determined at 0.5 ng/mL (Ly2452473), 1 ng/mL (AC-262536 and PF-06260414), 2 ng/mL (bicalutamide, GLPG0492, LGD-2226, ostarine, S-1, S-6, and S-23), and 5 ng/mL (andarine, BMS-564929, LGD-4033, RAD140, and S-9), respectively. The applicability of the developed assay was demonstrated through the analysis of blood samples from racehorses and cattle. The developed method presents a high-throughput cost-effective tool for the routine screening for a range of SARM compounds in sport and livestock animals.
Assuntos
Anabolizantes/análise , Androgênios/análise , Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas em Tandem/métodos , Anabolizantes/sangue , Androgênios/sangue , Animais , Bovinos , Cromatografia Líquida de Alta Pressão/economia , Análise Custo-Benefício , Dopagem Esportivo , Estabilidade de Medicamentos , Armazenamento de Medicamentos , Ensaios de Triagem em Larga Escala/economia , Cavalos , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/economiaRESUMO
Erythropoietins (EPOs) are substances listed in S2 of the World Anti-Doping Agency (WADA) Prohibited List and are used commonly by athletes to increase endurance performance. According to the current WADA Technical Documents, sarcosyl-polyacrylamide gel electrophoresis (SAR-PAGE) followed by western blotting to differentiate erythropoietins based on their molecular weights is the only method that can be used for both screening and confirmation of all types of erythropoietins. The efficiency of immunopurification and protein transfer is crucial for ensuring the selectivity and sensitivity of erythropoietin detection. Several comparisons and optimization of the SAR-PAGE tests were conducted in this study. We optimized the first blotting conditions and then compared different immunopurification methods based on their selectivity, repeatability, and sensitivity for both urine and blood analysis. Additionally, rapid procedures for both urine and blood analysis were established and compared. The two-step procedure at 1.0 mA/cm2 for 60 min followed by 1.56 mA/cm2 for 20 min increased the blotting efficiency compared with the commonly used constant current approach. Comparison of immunopurification revealed no significant difference in selectivity and sensitivity between the different methods. For other factors, such as operation complexity, time and cost, a StemCell® purification kit followed by single blotting and magnetic beads followed by double blotting are recommended for urine screening and confirmation, respectively. While magnetic beads and a MAIIA® kit followed by double blotting are recommended for both screening and confirmation of blood samples, respectively. To ensure high sensitivity and selectivity, double blotting is recommended for a rapid procedure for both urine and blood analysis.
Assuntos
Eletroforese em Gel de Poliacrilamida/métodos , Eritropoetina/sangue , Eritropoetina/urina , Western Blotting/economia , Western Blotting/métodos , Dopagem Esportivo , Eletroforese em Gel de Poliacrilamida/economia , Humanos , Reprodutibilidade dos Testes , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/métodos , Fatores de TempoRESUMO
BACKGROUND: The technical advantages of direct-to-definitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) urine testing for monitoring patient compliance in pain management are well known. However, the design and implementation of LC-MS/MS methods are more controversial, including factors such as determining appropriate cutoffs, specimen processing (e.g., specimen hydrolysis), reporting of qualitative and/or quantitative results, and test menu. OBJECTIVES: The objective of the research was to compare the clinical performance of our previous urine pain toxicology panel, a combination of immunoassay (IA) screens and LC-MS/MS, to our current pain toxicology panel, which features direct-to-definitive LC-MS/MS for 34 drugs and metabolites. STUDY DESIGN: Six months of results from our previous pain toxicology panel were compared to 5.5 months of results from our current pain toxicology panel, enabling us to make conclusions regarding clinical performance. SETTING: The research took place at Brigham and Women's Hospital in Boston, MA. METHODS: The percentage of false positive IA results was evaluated for our previous pain toxicology panel. The positivity rates for each drug and/or metabolite were calculated for both the previous and current panels, including rates of detection of both prescribed and illicit drugs. The turnaround time (TAT), direct and send-out costs associated with each approach, as well as projected cost savings were also determined. RESULTS: False positive rates with IA ranged from 0% to 29%; the highest false positive rate was seen for 6-acetylmorphine (6-AM). The elimination of IA, addition of metabolites, and/or lowering of cutoffs increased the detection rate of 6-AM, benzoylecgonine (cocaine metabolite), fentanyl, morphine, and oxycodone. The ability to differentiate compliance from simulated compliance improved after eliminating specimen hydrolysis. The TAT improved significantly and projected yearly cost savings with the current panel was $95,003 (USD). In our opinion, qualitative results appeared sufficient to assess compliance in the majority of cases. LIMITATIONS: Our study was performed in a single academic center in a specific geographic region; therefore, our results may not be generalizable to other types of centers or regions. CONCLUSION: Direct-to-definitive LC-MS/MS testing has several clinical benefits, including reduction of false positive results, improved assessment of patient compliance, decreased TAT, and increased detection of drug use and abuse. Cost savings were also realized using this approach. KEY WORDS: Direct-to-definitive, LC-MS/MS, immunoassay, sensitivity, cost, pain management, turnaround time, patient compliance.
Assuntos
Cromatografia Líquida/métodos , Imunoensaio/métodos , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos , Urinálise/métodos , Cromatografia Líquida/economia , Reações Falso-Positivas , Feminino , Humanos , Drogas Ilícitas/urina , Imunoensaio/economia , Manejo da Dor , Detecção do Abuso de Substâncias/economia , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/urina , Espectrometria de Massas em Tandem/economia , Urinálise/economiaRESUMO
Programs of drug testing welfare recipients are increasingly common in US states and have been considered elsewhere. Though often intensely debated, such programs are complicated to evaluate because their aims are ambiguous-aims like saving money may be in tension with aims like referring people to treatment. We assess such programs using a proportionality approach, which requires that for ethical acceptability a practice must be reasonably likely to meet its aims, sufficiently important in purpose as to outweigh harms incurred, and lower in costs than feasible alternatives. In the light of empirical findings, we argue that the programs fail the three requirements. Pursuing recreational drug users is not important in the light of costs incurred, while dependent users who may require referral are usually identifiable without testing and typically need a broader approach than one focussing on drugs. Drug testing of welfare recipients is therefore not ethically acceptable policy.
Assuntos
Dissidências e Disputas , Programas de Rastreamento/ética , Pobreza , Assistência Pública , Detecção do Abuso de Substâncias/ética , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Populações Vulneráveis , Custos e Análise de Custo , Objetivos , Humanos , Programas de Rastreamento/economia , Encaminhamento e Consulta , Detecção do Abuso de Substâncias/economiaRESUMO
In the last few years an increasing number of new psychoactive substances (NPS), with different chemical structures (of which 37% are stimulants), have been released into the illicit drug market. Their detection and identification in biological samples is hence of great concern. The aim of this work was to develop a high-throughput and rapid method for the determination of different classes of stimulants (amphetamine-type stimulants, cathinones, phenethylamines and ketamine analogues) from blood and urine samples using GC-MS. The proposed method allows the almost simultaneous derivatization and extraction of analytes from biological samples in a very short time, by using hexyl chloroformate as derivatization agent. The extraction of analytes was performed by Dispersive Liquid Liquid Microextraction (DLLME), a very rapid, cheap and efficient extraction technique that employs microliter amounts of organic solvents. The chromatographic method allowed for the separation of 26 stimulants including positional isomers (3-MMC and 4-MMC). The method was validated on urine and blood samples with the ability to detect and quantify all analytes with satisfactory limits of detection (LODs) ranging between 1 and 10ng/mL, limits of quantification (LOQs) between 2 and 50ng/mL, selectivity and linearity (5-1000ng/mL). The method was then applied to real samples from forensic cases, demonstrating its suitability for the screening of a wide number of stimulants in biological specimens.
Assuntos
Estimulantes do Sistema Nervoso Central/análise , Cromatografia Gasosa-Espectrometria de Massas/métodos , Drogas Ilícitas/análise , Detecção do Abuso de Substâncias/métodos , Alcaloides/análise , Anfetaminas/análise , Formiatos/química , Cromatografia Gasosa-Espectrometria de Massas/economia , Humanos , Limite de Detecção , Microextração em Fase Líquida/economia , Microextração em Fase Líquida/métodos , Detecção do Abuso de Substâncias/economia , Fatores de TempoRESUMO
A study was previously conducted and published describing the magnitude of the under-reporting of drugs in driving under the influence (DUI) cases by using a blood drug screen (BDS) case management protocol and to determine whether not reporting those drugs would have a meaningful impact on the DUI cases. A follow-up study presented herein was conducted to generate a larger dataset for evaluation and to compare the results to the original study. For this follow-up study of 576 cases, the laboratory BDS protocol was modified so that a BDS was performed for all felony cases and all misdemeanor cases with a BAC < 0.15 g/dL, regardless of the officer's request. A cost analysis estimate was also conducted using purchasing and statistical data for calendar year 2014. It was estimated that on average a BDS had a materials cost 30 times greater than a BAC and required over six times as much analyst time. To perform a BDS on every case as has been recommended, the estimated analysis materials cost and analyst time were 218 and 193% of the old protocol, respectively. The results of this follow-up study futher support the insufficiency of presenting drug positivity as a justification for completing drug analysis on every DUI case. For the vast majority of cases with a BAC > 0.08 g/dL, the drugs detected are not significant for supporting a DUI and do not warrant the substantial increase in analysis cost and time required.
Assuntos
Administração de Caso/economia , Dirigir sob a Influência/estatística & dados numéricos , Toxicologia Forense/economia , Laboratórios/economia , Detecção do Abuso de Substâncias/economia , Intoxicação Alcoólica , Análise Custo-Benefício , Detecção do Abuso de Substâncias/métodos , Detecção do Abuso de Substâncias/estatística & dados numéricosRESUMO
BACKGROUND: Many users believe that synthetic cannabinoids offer a safe and legal means of getting high. However, spikes in emergency department visits have been associated with use of synthetic cannabinoids. The purpose of the current study was to document emergency department visits from three large hospitals in one metropolitan area over a two month period. METHOD: This was a retrospective chart review examining 218 patients presenting to three inner city emergency departments between March and April 2014. Data collected included demographic information, information regarding ED diagnosis and treatment, signs and symptoms, ancillary testing, ED disposition, and cost of the medical treatment. RESULTS: The majority of patients (75.7%) were discharged after ED workup, but 12.4% were admitted for medical treatment and 11.5% were admitted for psychiatric treatment. Ten patients (4.6%) were admitted to the ICU. Symptoms experienced most frequently include: hypertension, tachycardia, agitation, drowsiness, nausea, and confusion. Cluster analysis revealed four symptom clusters of individuals presenting after using synthetic cannabinoids: 1) confusion, hostility, agitation, 2) nausea, vomiting, abdominal pain, 3) drowsiness, and 4) the absence of these symptoms. CONCLUSION: This study has three important findings. First, significant ED resources are being used to treat individuals presenting due to effects of synthetic cannabis. Second, synthetic cannabis is not a benign substance. Third, while the hostile and agitated user is generally presented in the media, this study finds significant heterogeneity in presentation. Further research is needed to fully understand the implications of synthetic cannabinoid use.
Assuntos
Canabinoides/síntese química , Canabinoides/farmacologia , Serviço Hospitalar de Emergência/estatística & dados numéricos , Custos Hospitalares/tendências , Hospitalização/estatística & dados numéricos , Detecção do Abuso de Substâncias/economia , Transtornos Relacionados ao Uso de Substâncias/economia , Adolescente , Adulto , Idoso , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Estados Unidos/epidemiologia , Adulto JovemRESUMO
Lysergic acid diethylamide (LSD) is a semi-synthetic hallucinogen that has gained popularity as a recreational drug and has been investigated as an adjunct to psychotherapy. Analysis of LSD represents a major challenge in forensic toxicology due to its instability, low drug concentrations, and short detection windows in biological samples. A new, fast, and sensitive microflow liquid chromatography (MFLC) tandem mass spectrometry method for the validated quantification of LSD, iso-LSD, 2-oxo 3-hydroxy-LSD (oxo-HO-LSD), and N-desmethyl-LSD (nor-LSD) was developed in plasma and applied to a controlled pharmacokinetic (PK) study in humans to test whether LSD metabolites would offer for longer detection windows. Five hundred microlitres of plasma were extracted by solid phase extraction. Analysis was performed on a Sciex Eksigent MFLC system coupled to a Sciex 5500 QTrap. The method was validated according to (inter)-national guidelines. MFLC allowed for separation of the mentioned analytes within 3 minutes and limits of quantification of 0.01 ng/mL. Validation criteria were fulfilled for all analytes. PK data could be calculated for LSD, iso-LSD, and oxo-HO-LSD in all participants. Additionally, hydroxy-LSD (HO-LSD) and HO-LSD glucuronide could be qualitatively detected and PK determined in 11 and 8 subjects, respectively. Nor-LSD was only sporadically detected. Elimination half-lives of iso-LSD (median 12 h) and LSD metabolites (median 9, 7.4, 12, and 11 h for oxo-HO-LSD, HO-LSD, HO-LSD-gluc, and nor-LSD, respectively) exceeded those of LSD (median 4.2 h). However, screening for metabolites to increase detection windows in plasma seems not to be constructive due to their very low concentrations. Copyright © 2016 John Wiley & Sons, Ltd.
Assuntos
Alucinógenos/sangue , Alucinógenos/metabolismo , Dietilamida do Ácido Lisérgico/sangue , Dietilamida do Ácido Lisérgico/metabolismo , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/economia , Cromatografia Líquida/métodos , Humanos , Limite de Detecção , Dietilamida do Ácido Lisérgico/análogos & derivados , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/economia , Fatores de TempoRESUMO
A rapid, simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the qualitative and quantitative analysis of nine barbiturates (barbital, phenobarbital, pentobarbital, amobarbital, secobarbital, thiopental, butalbital, butabarbital, and hexobarbital) in human whole blood. Barbiturates were extracted from 100 µL of human whole blood samples using a simple liquid-liquid extraction (LLE) procedure, and detected by LC-MS/MS. An UPLC C18 (2.1 mm × 100 mm, 1.7 µm) column was used at 40 °C for the separation and acetonitrile/water system was used as the mobile phase with gradient elution. This method showed excellent accuracy (86-111%) and precision (relative standard deviation <15%). The limits of detection (LODs) were 0.2 ng/mL for barbital and secobarbital and 0.5 ng/mL for the other barbiturates. The linearity ranged from 2 ng/mL to 2000 ng/mL, with r2 > 0.99 over the range. This method achieved the separation and detection of pentobarbital and amobarbital at the same time in a convenient way. Moreover, it was both simple and sensitive for the determination of nine most commonly used barbiturate drugs, which was meaningful in the field of clinical and forensic toxicology. Copyright © 2016 John Wiley & Sons, Ltd.
Assuntos
Barbitúricos/sangue , Cromatografia Líquida/métodos , Hipnóticos e Sedativos/sangue , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/economia , Toxicologia Forense/economia , Toxicologia Forense/métodos , Humanos , Limite de Detecção , Masculino , Pessoa de Meia-Idade , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/economia , Fatores de TempoRESUMO
We describe the development and validation of a method for the screening and confirmation of a range of chemically diverse synthetic cannabinoid drugs in human whole blood. The method targets the better known arylindole compounds as well as the emerging aminocarbonyl/ carboxamide (NACA) compounds. The approach consists of two separate extraction procedures designed to optimize recovery of each of these two classes, followed by analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The most significant novel compounds added were AB-FUBINACA, ADBICA, 5 F-ADBICA, ADB-PINACA, ADB-FUBINACA, ADB-FUBINACA, 5 F-ADB-PINACA, 5 F-ADB-PINACA, AB-PINACA, AB-CHMINACA, and ADB-CHMINACA. A third procedure is described for the quantitative confirmation of those compounds for which deuterated internal standards permitted quantitative analysis, including JWH-018, JWH-122, JWH-081, JWH-210, AM-2201, XLR-11, and UR-144. The methods were successfully validated according to Scientific Working Group in Forensic Toxicology (SWGTOX) protocol for 34 compounds in common use in the United States in the period of 2014 and 2015, although other substances, unknown at the time may have been introduced to the market over the same time period. The method was determined to be free from carry-over between samples, and no interference was found from other common therapeutic abused or novel psychoactive drugs. The methods were applied to the analysis of 1142 blood samples from forensic investigations, including post-mortem examinations and driving impairment cases. The drugs most frequently detected were AB-CHMINACA (18.6%), ADB-CHMINACA (15%), XLR-11 (5.5%), AB-FUBINACA (4.5%), AB-PINACA (3.9%), and ADB-FUBINACA (2.3%). Copyright © 2016 John Wiley & Sons, Ltd.
Assuntos
Canabinoides/sangue , Drogas Ilícitas/sangue , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/economia , Cromatografia Líquida/métodos , Toxicologia Forense/economia , Toxicologia Forense/métodos , Humanos , Limite de Detecção , Detecção do Abuso de Substâncias/economia , Espectrometria de Massas em Tandem/economia , Fatores de TempoRESUMO
A rapid and direct paper spray ionization/mass spectrometry (PSI/MS) method was developed for quantitative analysis of ephedrine, pseudoephedrine, norpseudoephedrine, and methylephedrine in human urine. This method involves the use of a triangular filter paper and high-resolution mass spectrometry, where the molecular ions of ephedrines were generated by applying high voltage after loading the spray solvent to the paper which urine sample was pre-loaded. Small amounts (2µL) of urine spiked with an internal standard were directly analyzed for ephedrines. The PSI/MS method was validated for linearity, within- and between-run precision, accuracy, and limit of detection. The results showed good linearity (R(2)≥0.9928) and acceptable precision and accuracy. Furthermore, the accuracy of the method was assessed by analyzing a blind urine sample from World Anti-Doping Agency and comparing the measured concentrations with the nominal concentrations. This test resulted in accuracies ranging from 96.4 to 106.1%, indicating that the PSI/MS method has the potential to be an alternative technique for the fast quantitation of ephedrines in doping control analysis.
Assuntos
Estimulantes do Sistema Nervoso Central/urina , Efedrina/análogos & derivados , Efedrina/urina , Espectrometria de Massas/métodos , Fenilpropanolamina/urina , Pseudoefedrina/urina , Detecção do Abuso de Substâncias/métodos , Humanos , Limite de Detecção , Espectrometria de Massas/economia , Papel , Reprodutibilidade dos Testes , Detecção do Abuso de Substâncias/economiaAssuntos
Miniaturização/instrumentação , Análise Espectral/instrumentação , Monitoramento Ambiental/economia , Monitoramento Ambiental/instrumentação , Humanos , Análise Espectral/economia , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/instrumentação , Fatores de Tempo , Tecnologia sem Fio/economia , Tecnologia sem Fio/instrumentaçãoRESUMO
We present a UPLC(®)-High Resolution Mass Spectrometric method to simultaneously screen for nineteen benzodiazepines, twelve opiates, cocaine and three metabolites, and three "Z-drug" hypnotic sedatives in both blood and urine specimens. Sample processing consists of a high-speed, high-temperature enzymatic hydrolysis for urine samples followed by a rapid supported liquid extraction (SLE). The combination of ultra-high resolution chromatography with high resolution mass spectrometry allows all 38 analytes to be uniquely detected with a ten minute analytical run. Limits of detection for all target analytes are 3ng/mL or better, with only 0.3mL of specimen used for analysis. The combination of low sample volume with fast processing and analysis makes this method a suitable replacement for immunoassay screening of the targeted drug classes, while providing far superior specificity and better limits of detection than can routinely be obtained by immunoassay.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas por Ionização por Electrospray/métodos , Detecção do Abuso de Substâncias/métodos , Benzodiazepinas/sangue , Benzodiazepinas/urina , Cromatografia Líquida de Alta Pressão/economia , Cromatografia Líquida de Alta Pressão/instrumentação , Cocaína/sangue , Cocaína/urina , Desenho de Equipamento , Humanos , Hipnóticos e Sedativos/sangue , Hipnóticos e Sedativos/urina , Limite de Detecção , Alcaloides Opiáceos/sangue , Alcaloides Opiáceos/urina , Espectrometria de Massas por Ionização por Electrospray/economia , Espectrometria de Massas por Ionização por Electrospray/instrumentação , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/instrumentação , Fatores de TempoRESUMO
The concentration of 11-nor-9-carboxy-Δ(9)-tetrahydrocannabinol (THCCOOH) in whole blood is used as a parameter for assessing the consumption behavior of cannabis consumers. The blood level of THCCOOH-glucuronide might provide additional information about the frequency of cannabis use. To verify this assumption, a column-switching liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the rapid and direct quantification of free and glucuronidated THCCOOH in human whole blood was newly developed. The method comprised protein precipitation, followed by injection of the processed sample onto a trapping column and subsequent gradient elution to an analytical column for separation and detection. The total LC run time was 4.5 min. Detection of the analytes was accomplished by electrospray ionization in positive ion mode and selected reaction monitoring using a triple-stage quadrupole mass spectrometer. The method was fully validated by evaluating the following parameters: linearity, lower limit of quantification, accuracy and imprecision, selectivity, extraction efficiency, matrix effect, carry-over, dilution integrity, analyte stability, and re-injection reproducibility. All acceptance criteria were analyzed and the predefined criteria met. Linearity ranged from 5.0 to 500 µg/L for both analytes. The method was successfully applied to whole blood samples from a large collective of cannabis consumers, demonstrating its applicability in the forensic field.
Assuntos
Cromatografia Líquida de Alta Pressão/instrumentação , Dronabinol/análogos & derivados , Glucuronídeos/sangue , Fumar Maconha/sangue , Espectrometria de Massas em Tandem/instrumentação , Cannabis/química , Cromatografia Líquida de Alta Pressão/economia , Cromatografia Líquida de Alta Pressão/métodos , Dronabinol/sangue , Desenho de Equipamento , Humanos , Limite de Detecção , Reprodutibilidade dos Testes , Detecção do Abuso de Substâncias/economia , Detecção do Abuso de Substâncias/instrumentação , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/economia , Espectrometria de Massas em Tandem/métodosRESUMO
In recent years, many new psychoactive substances (NPS) from several drug classes have appeared on the drug market. These substances, also known as 'legal highs', belong to different chemical classes. Despite the increasing number of NPS, there are few comprehensive screening methods for their detection in biological specimens. In this context, the purpose of this study was to develop a fast and simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening procedure for NPS in blood. The elaborated method allows the simultaneous screening of 143 compounds from different groups (number of compounds): cathinones (36), phenethylamines (26), tryptamines (18), piperazines (9), piperidines (2), synthetic cannabinoids (34), arylalkylamines (7), arylcyclohexylamines (3), aminoindanes (2), and other drugs (6). Blood samples (0.2 mL) were precipitated with acetonitrile (0.6 mL). The separation was achieved with gradient mobile phase of 0.1% formic acid in acetonitrile and 0.1% formic acid in water in 14 min. Detection of all compounds was based on multiple reaction monitoring (MRM) transitions. The total number of transitions monitored in dynamic mode was 432. The whole procedure was rapid and simple. The limits of detection (LODs) estimated for 104 compounds were in the range 0.01-3.09 ng/mL. The extraction recoveries determined for 32 compounds were from 1.8 to 133%. The procedure was successfully applied to the analysis of forensic blood samples in routine casework. The developed method should have wide applicability for rapid screening of new drugs of abuse in forensic or clinical samples. The procedure can be easily expanded for more substances. Copyright © 2015 John Wiley & Sons, Ltd.
Assuntos
Cromatografia Líquida/métodos , Drogas Ilícitas/sangue , Psicotrópicos/sangue , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/economia , Humanos , Limite de Detecção , Detecção do Abuso de Substâncias/economia , Espectrometria de Massas em Tandem/economia , Fatores de TempoRESUMO
Drug screening is an essential component of clinical toxicology laboratory service. Some laboratories use only automated chemistry analyzers for limited screening of drugs of abuse and few other drugs. Other laboratories use a combination of various techniques such as immunoassays, colorimetric tests, and mass spectrometry to provide more detailed comprehensive drug screening. Mass spectrometry, gas or liquid, can screen for hundreds of drugs and is often considered the gold standard for comprehensive drug screening. We describe an efficient and rapid gas chromatography/mass spectrometry (GC/MS) method for comprehensive drug screening in urine which utilizes a liquid-liquid extraction, sample concentration, and analysis by GC/MS.
Assuntos
Cromatografia Gasosa-Espectrometria de Massas/métodos , Detecção do Abuso de Substâncias/métodos , Urinálise/métodos , Cromatografia Gasosa-Espectrometria de Massas/economia , Humanos , Extração Líquido-Líquido/economia , Extração Líquido-Líquido/métodos , Detecção do Abuso de Substâncias/economia , Fatores de Tempo , Urinálise/economiaRESUMO
The author argues that drug testing of U.S. high school students for performance-enhancing substance misuse is invasive, expensive, and the low number of positive test results do not justify the costs, especially in financially strapped school districts where this money would be better spent on injury prevention for athletes and the education of all students.
Assuntos
Atletas , Dopagem Esportivo , Substâncias para Melhoria do Desempenho , Estudantes , Detecção do Abuso de Substâncias/métodos , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Adolescente , Anabolizantes , Estimulantes do Sistema Nervoso Central , Análise Custo-Benefício , Eritropoetina , Hematínicos , Humanos , Instituições Acadêmicas/economia , Detecção do Abuso de Substâncias/economia , Estados UnidosRESUMO
The anti-doping system, under the guidance of WADA, costs at least $228 million per year, mostly to cover the cost of performing about 270,000 doping tests. However, "testing has not proven to be particularly effective in detecting dopers/cheats" (WADA). It is suggested, competitions of doping-endangered disciplines be redesigned. Sports with numerous doping cases should be temporarily excluded from the Olympic program and not be televised. Pecuniary fines should be higher and collection guaranteed by a deferred compensation model. Sports with multiple doping offenses should bear most of the anti-doping costs. Finally, appropriate tenders should guarantee fees of anti-doping laboratories develop more competitively.